Andexanet alfa + Usual Care
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urgent Surgery
Conditions
Urgent Surgery
Trial Timeline
Aug 2, 2024 → Sep 7, 2027
NCT ID
NCT05926349About Andexanet alfa + Usual Care
Andexanet alfa + Usual Care is a phase 3 stage product being developed by AstraZeneca for Urgent Surgery. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05926349. Target conditions include Urgent Surgery.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05926349 | Phase 3 | Withdrawn |